Early Intervention vs. Standard Palliative Care in Improving End-of-Life Care in Advanced Cancer Patients

NCT ID: NCT00253383

Last Updated: 2014-12-19

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

329 participants

Study Classification

INTERVENTIONAL

Study Start Date

2003-01-31

Study Completion Date

2013-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

RATIONALE: Palliative care may help patients with advanced cancer live more comfortably.

PURPOSE: This randomized clinical trial is studying an early intervention palliative care program to see how well it works compared to a standard care program in improving end-of-life care in patients with advanced lung , gastrointestinal, genitourinary, or breast cancer.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

OBJECTIVES:

* Determine the efficacy of an early intervention palliative care program comprising a phone-based nurse educator and shared medical appointments in improving end-of-life care of patients with advanced lung, gastrointestinal, genitourinary, or breast cancer.
* Compare symptom management, quality of life, and the match between preference of care and the care received in patients treated with an early intervention palliative care program vs a standard care program.
* Compare health care utilization by patients treated with these interventions.

OUTLINE: This is a randomized, multicenter study. Patients are stratified according to cancer diagnosis (lung vs breast vs gastrointestinal vs genitourinary) and participating center. Patients are randomized to 1 of 2 intervention arms.

* Arm I (early-intervention palliative care program): Patients complete the Medical Care Questionnaire and receive a computer-generated prescription letter that outlines the problems they have identified; the patient's physician also receives a copy of the letter. Patients receive a series of phone calls weekly for 4 weeks and then at least monthly from a nurse educator. The phone calls address 3 major areas: coordination of palliative care options in the cancer center and the patient's community, including referrals for psychological or spiritual counseling, social work consultation, financial guidance, home health, palliative care or hospice services, and bereavement counseling for the family; problem-solving therapy, focusing on the identification of problems, definition of achievable goals, a plan for reaching those goals, and evaluation of success; and tailored psycho-educational modules from "Charting Your Course", covering end-of-life topics such as symptom management, advanced care planning, communication with the health care team and family members, spirituality, and nutrition. Patients also receive information regarding the purpose and time/location of symptom management, shared medical appointments (SMAs), which they can attend in person or call in to participate via speaker phone. SMAs are 1.5-hour monthly sessions conducted by a physician and a nurse practitioner that can accommodate 10-12 patients and their caregivers. The sessions include a welcome/social period, a question and answer/peer discussion, an interactive educational session, and an opportunity for one-on-one nurse practitioner appointments with a focus on a brief review of the patients' medical treatment plans.
* Arm II (standard palliative care program): Patients receive standard palliative care from their physician/nurse practitioner team and have access to the palliative care nurse at the discretion of the treating physician.

Patients complete Functional Assessment of Chronic Illness Therapy-Palliative Care at baseline and every 3 months thereafter. Patients and caregivers complete surveys measuring their perception of the quality of the patient's cancer care at baseline and at 1 month.

A caregiver or family member completes the After-Death Bereaved Family Member Interview to evaluate the adequacy of patient care at 3 months post-patient death.

PROJECTED ACCRUAL: A total of 450 patients will be accrued for this study.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cancer

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

transitional care planning stage IIIB non-small cell lung cancer stage IV non-small cell lung cancer extensive stage small cell lung cancer stage IV breast cancer recurrent breast cancer male breast cancer stage IIIB anal cancer stage IV anal cancer carcinoma of the appendix stage III colon cancer stage IV colon cancer stage III rectal cancer stage IV rectal cancer stage III esophageal cancer stage IV esophageal cancer unresectable extrahepatic bile duct cancer unresectable gallbladder cancer stage III gastric cancer stage IV gastric cancer metastatic gastrointestinal carcinoid tumor regional gastrointestinal carcinoid tumor gastrointestinal stromal tumor advanced adult primary liver cancer localized unresectable adult primary liver cancer stage III pancreatic cancer recurrent small intestine cancer small intestine adenocarcinoma small intestine leiomyosarcoma small intestine lymphoma stage IV bladder cancer stage IV renal cell cancer clear cell sarcoma of the kidney peripheral primitive neuroectodermal tumor of the kidney rhabdoid tumor of the kidney metastatic transitional cell cancer of the renal pelvis and ureter anterior urethral cancer posterior urethral cancer urethral cancer associated with invasive bladder cancer stage IV penile cancer stage IV prostate cancer stage III malignant testicular germ cell tumor stage IV endometrial carcinoma fallopian tube cancer ovarian sarcoma ovarian stromal cancer stage IV pancreatic cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

ENABLE (concurrent palliative care)

telephone based ENABLE educational intervention

Group Type EXPERIMENTAL

counseling intervention

Intervention Type OTHER

educational intervention

Intervention Type OTHER

psychosocial assessment and care

Intervention Type PROCEDURE

quality-of-life assessment

Intervention Type PROCEDURE

Usual Care

Supportive and palliative usual care services at DHMC, Behavioral

Group Type ACTIVE_COMPARATOR

counseling intervention

Intervention Type OTHER

psychosocial assessment and care

Intervention Type PROCEDURE

quality-of-life assessment

Intervention Type PROCEDURE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

counseling intervention

Intervention Type OTHER

educational intervention

Intervention Type OTHER

psychosocial assessment and care

Intervention Type PROCEDURE

quality-of-life assessment

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

DISEASE CHARACTERISTICS:

* Diagnosis of 1 of the following advanced cancers:

* Stage IIIB or IV non-small cell lung cancer
* Extensive stage small cell lung cancer
* Stage IV breast cancer

* Poor prognostic indicators (conferring likelihood of ≤ 2 years survival), including, but not limited to, any of the following:

* Visceral crisis
* Lung or liver metastasis
* Estrogen receptor-negative disease
* HER2/neu-positive disease
* Progressive or recurrent disease during or within 2 years of first treatment
* Unresectable stage III or stage IV gastrointestinal cancers
* Stage IV genitourinary cancers

* Prostate cancer must be hormone refractory
* Hormone receptor status:

* Not specified

PATIENT CHARACTERISTICS:

Sex

* Not specified

Menopausal status

* Not specified

Performance status

* Not specified

Life expectancy

* Not specified

Hematopoietic

* Not specified

Hepatic

* Not specified

Renal

* Not specified

Other

* No dementia or significant confusion (i.e., Mini Mental Exam score \< 25)
* No Axis I psychiatric disorders (DSM-IV), including any of the following:

* Schizophrenia
* Bipolar disorder
* Active substance use disorder

PRIOR CONCURRENT THERAPY:

Endocrine therapy

* See Disease Characteristics
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

National Cancer Institute (NCI)

NIH

Sponsor Role collaborator

Dartmouth-Hitchcock Medical Center

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Marie A Bakitas, PhD

Role: PRINCIPAL_INVESTIGATOR

Norris Cotton Cancer Center

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Norris Cotton Cancer Center at Dartmouth-Hitchcock Medical Center

Lebanon, New Hampshire, United States

Site Status

Veterans Affairs Medical Center - White River Junction

White River Junction, Vermont, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

References

Explore related publications, articles, or registry entries linked to this study.

Bakitas M, Lyons KD, Hegel MT, Balan S, Brokaw FC, Seville J, Hull JG, Li Z, Tosteson TD, Byock IR, Ahles TA. Effects of a palliative care intervention on clinical outcomes in patients with advanced cancer: the Project ENABLE II randomized controlled trial. JAMA. 2009 Aug 19;302(7):741-9. doi: 10.1001/jama.2009.1198.

Reference Type RESULT
PMID: 19690306 (View on PubMed)

Corn BW, Feldman DB, Hull JG, O'Rourke MA, Bakitas MA. Dispositional hope as a potential outcome parameter among patients with advanced malignancy: An analysis of the ENABLE database. Cancer. 2022 Jan 15;128(2):401-409. doi: 10.1002/cncr.33907. Epub 2021 Oct 6.

Reference Type DERIVED
PMID: 34613617 (View on PubMed)

Prescott AT, Hull JG, Dionne-Odom JN, Tosteson TD, Lyons KD, Li Z, Li Z, Dragnev KH, Hegel MT, Steinhauser KE, Ahles TA, Bakitas MA. The role of a palliative care intervention in moderating the relationship between depression and survival among individuals with advanced cancer. Health Psychol. 2017 Dec;36(12):1140-1146. doi: 10.1037/hea0000544. Epub 2017 Oct 19.

Reference Type DERIVED
PMID: 29048177 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

R01CA101704

Identifier Type: NIH

Identifier Source: secondary_id

View Link

P30CA023108

Identifier Type: NIH

Identifier Source: secondary_id

View Link

DMS-0226

Identifier Type: -

Identifier Source: secondary_id

DMS-CPHS-16004

Identifier Type: -

Identifier Source: secondary_id

CDR0000452966

Identifier Type: -

Identifier Source: org_study_id